-
Neurology Dec 1975Isoniazid inhibited the metabolism of primidone in a patient with focal seizures. The steady-state serum level of primidone rose when the patient received both drugs...
Isoniazid inhibited the metabolism of primidone in a patient with focal seizures. The steady-state serum level of primidone rose when the patient received both drugs simultaneoulsy. The serum levels of the primidone metabolites, phenobarbital and phenylethylmalonamide, fell and the rate of metabolism of primidone decreased. The results are similar to those observed when isoniazid is adminstered with diphenylhydantoin.
Topics: Depression, Chemical; Drug Therapy, Combination; Epilepsies, Partial; Female; Humans; Isoniazid; Middle Aged; Phenobarbital; Phenylethylmalonamide; Phenytoin; Primidone; Pyridoxine; Tuberculosis, Miliary
PubMed: 812007
DOI: 10.1212/wnl.25.12.1179 -
Journal - Forensic Science Society Apr 1965
Topics: Forensic Medicine; Poisoning; Primidone; Toxicology
PubMed: 14328690
DOI: 10.1016/s0015-7368(65)70250-8 -
Canadian Medical Association Journal Nov 1981
Topics: Bipolar Disorder; Female; Humans; Lithium; Primidone; Tremor
PubMed: 7332893
DOI: No ID Found -
American Journal of Health-system... Jul 2022We report a unique case of transiently elevated liver function test (LFT) values associated with concurrent use of dabigatran and primidone, which has not previously...
PURPOSE
We report a unique case of transiently elevated liver function test (LFT) values associated with concurrent use of dabigatran and primidone, which has not previously been described in the scientific literature.
SUMMARY
Management of drug-drug interactions requires a fundamental understanding of pharmacodynamic and pharmacokinetic parameters. Despite the use of available best predictive models, idiosyncratic drug reactions may still occur when a newly approved medication begins to be used in the general population. We report a case of a possible interaction (Naranjo adverse drug reaction probability score of 3, Roussel Uclaf causality assessment method score of 3) between dabigatran and primidone in a 70-year-old Caucasian male resulting in a transient elevation of LFT values. The patient was transitioned from warfarin to dabigatran in the setting of persistently subtherapeutic international normalized ratio values. During a routine outpatient follow-up appointment approximately 1 month after dabigatran initiation, the patient was discovered to have LFT values greater than 5 times the upper limit of normal. Dabigatran was thus discontinued; the patient was returned to warfarin therapy and their LFT values returned to baseline.
CONCLUSION
Studies have indicated a potential for reduced dabigatran efficacy with concurrent use of primidone due to P-glycoprotein induction, thereby potentiating the risk for thrombosis. To date, reports of this interaction resulting in hepatic injury are lacking. The present case suggests that this interaction may be clinically significant with regard to selection of antithrombotic medication therapy in patients on primidone therapy.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; International Normalized Ratio; Liver Function Tests; Male; Primidone; Warfarin
PubMed: 35212353
DOI: 10.1093/ajhp/zxac054 -
The New England Journal of Medicine Feb 1956
Topics: Epilepsy; Humans; Primidone
PubMed: 13288784
DOI: 10.1056/NEJM195602162540706 -
Lancet (London, England) Oct 1993
Topics: Bipolar Disorder; Emotions; Female; Humans; Middle Aged; Primidone
PubMed: 8105181
DOI: 10.1016/0140-6736(93)91972-o -
The Journal of Pediatrics May 1982
Topics: Abnormalities, Drug-Induced; Diagnosis, Differential; Female; Humans; Infant, Newborn; Noonan Syndrome; Pregnancy; Prenatal Exposure Delayed Effects; Primidone
PubMed: 7069554
DOI: 10.1016/s0022-3476(82)80609-4 -
British Medical Journal (Clinical... Jul 1981
Clinical Trial Randomized Controlled Trial
Topics: Adult; Aged; Clinical Trials as Topic; Humans; Malonates; Middle Aged; Phenylethylmalonamide; Primidone; Tremor
PubMed: 6789979
DOI: 10.1136/bmj.283.6285.234-b -
British Medical Journal (Clinical... Feb 1981
Topics: Humans; Primidone; Tremor
PubMed: 6781643
DOI: 10.1136/bmj.282.6265.740-b -
BMJ Clinical Evidence May 2007Essential tremor is one of the most common movement disorders throughout the world, with prevalence in the general population of 0.4-3.9%. Although most people with... (Review)
Review
INTRODUCTION
Essential tremor is one of the most common movement disorders throughout the world, with prevalence in the general population of 0.4-3.9%. Although most people with essential tremor are only mildly affected, those who seek medical care are disabled to some extent, and most are socially handicapped by the tremor.
METHODS AND OUTCOMES
We conducted a systematic review and aimed to answer the following clinical question: What are the effects of drug treatments in people with essential tremor of the hand? We searched: Medline, Embase, The Cochrane Library and other important databases up to December 2006 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS
We found 41 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS
In this systematic review we present information relating to the effectiveness and safety of the following interventions: adding mirtazepine to other antitremor drugs; benzodiazepines; beta-blockers other than propranolol; botulinum A toxin-haemagglutinin complex; calcium channel blockers; carbonic anhydrase inhibitors; clonidine; flunarizine; gabapentin; isoniazid; Phenobarbital; primidone; propranolol; and topiramate.
Topics: Double-Blind Method; Essential Tremor; Humans; Primidone; Propranolol; Tremor
PubMed: 19454072
DOI: No ID Found